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Patients infected with multidrug-resistant Entero-
bacteriaceae were, until recently and with relative 
success, treated with carbapenems, a class of broad-
spectrum β-lactam antibiotics. Of great concern is 
the over-use of carbapenems in hospitals for treating 
Gram-negative bacterial infections, which is contributing to the 
increasing emergence of carbapenem resistance.[1]
Carbapenem resistance in Klebsiella spp. is mainly attributable to the 
acquisition of carbapenem-hydrolysing β-lactamase enzymes. The Ambler 
classification scheme is used to separate these enzymes into classes A, B 
or D.[3] The OXA-48-like subgroup, of which OXA-181 is a member, are 
Ambler class D carbapenemases.[3] OXA-48 was first described in the 
environmental bacterium Shewanella spp., and more recently there have 
been several reports of this enzyme, mainly in K. pneumoniae isolates, from 
countries in the Middle East, Europe, and northern and southern Africa.[4-7]
OXA-181, a variant of OXA-48, was first identified in K. 
pneumoniae isolated from a Tanzanian patient.[7] It differs by just 
four amino acid substitutions in the active site, yet still confers 
the same levels of enzymatic hydrolysis of carbapenems as OXA-
48. [7] Several international studies have identified OXA-181-producing 
Enterobacteriaceae in the UK, the Sultanate of Oman, the Netherlands, 
Senegal and New Zealand.[7-12] The genetic location of blaOXA-181 is 
typically on a Tn2013 transposon, immediately downstream of the 
insertion sequence ISEcp1B, carried on a 7.6-Kb, ColE-type plasmid.[7]
The prevalence of nosocomial infections in African countries has 
been under-appreciated in the past, and while such outbreaks occurring 
internationally are frequently reported in the literature, relatively few 
of these reports originate from developing countries. [13] However, even 
in lower-income countries, outbreak reports are necessary to increase 
awareness in the local medical community and highlight the need for 
enforced and effective infection prevention and control (IPAC) measures 
to limit the occurrence and transmission of antibiotic-resistant pathogens. 
OXA-48-like carbapenem-resistant Enterobacteriaceae are endemic 
worldwide but had not previously been observed in our hospital. A 
subsequent report indicates that such organisms had recently been 
detected in other local institutions.[6] This outbreak report serves as the 
first description and characterisation of a single outbreak of carbapenem-
resistant K. pneumoniae in a haematology unit of a local hospital in Cape 
Town, South Africa (SA), during the month of May 2012.
Objectives
Following the identification of a possible outbreak of carbapenem-
resistant Klebsiella spp. in a haematology unit in Cape Town, an 
epidemiological investigation was done to describe the extent of 
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Background. Klebsiella pneumoniae is an opportunistic pathogen often associated with nosocomial infections. A suspected outbreak of 
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obtained from seven patients, all from a single unit. These isolates were indistinguishable using PFGE analysis and belonged to sequence 
type ST-14. No other carbapenemase enzymes were detected.
Conclusion. This is the first documented laboratory-confirmed outbreak of OXA-181-producing K. pneumoniae in SA, and highlights 
the importance of enforcing strict adherence to infection control procedures and the need for ongoing surveillance of antibiotic-resistant 
pathogens in local hospitals.
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the outbreak, ascertain possible transmission 
routes and identify opportunities to prevent 
further transmission. Laboratory studies were 
carried out to characterise the molecular basis 
for carbapenem resistance and the molecular 
epidemiology of these isolates.
Methods
This was a prospective study, implemented 
informally in response to the detection on 12 
May 2012 of carbapenem-resistant Klebsiella 
spp. from two patients in the haematology 
intensive care unit (ICU) of a 900-bed 
tertiary care referral hospital in Cape Town.
The haematology ICU is utilised by 
high-risk haematology patients, either with 
haematological malignancies or undergoing 
stem cell transplants, typically when neutro-
penic. Patients from both the public hospital 
and the adjacent private hospital are admitted 
and nursed in 12 patient isolation rooms by staff 
from the public or private hospitals, respectively. 
However, both teams of staff share communal 
work areas within the unit, including the nurses’ 
station, the sluice room and staff rooms. The 
unit is supported by infection control staff from 
both private and public hospitals.
Following the identification of carbapenem-
resistant Klebsiella, an immediate and intensive 
outbreak response was implemented. Infection 
control measures were intensified, patient 
movement in and out of the affected unit 
was halted, and 2 weeks later it was closed for 
decontamination, maintenance and repairs.
A policy for weekly stool or rectal swab 
sur veillance for carbapenem-resistant Entero -
bacteriaceae for all haematology and oncol-
ogy inpatients (in either the ICU or the asso-
ciated wards) was already in place prior to 
May 2012. Laboratory records were checked 
for any previous carbapenem-resistant 
Enterobacteriaceae isolates from both clini-
cal and surveillance specimens. Surveillance 
was intensified, and stool samples were also 
obtained from staff members to screen for 
possible gut carriage. Environmental sam-
pling was not conducted as a previous out-
break suggested very limited benefit.[14]
For the outbreak a case was defined as a 
patient with carbapenem-resistant Klebsiella 
isolated from a clinical specimen (provider 
requested) or surveillance (routine screening) 
culture from the shared haematology ICU 
from 1 to 31 May 2012. A retrospective 
review of hospital records was performed 
for each case patient admitted before 31 May 
2012. Demographic, clinical, and laboratory 
information was abstracted from case patient 
charts, with all data being collected in the 
same manner as in the outbreak reported by 
Marchaim et al.[15] in 2011. Details of the eight 
patients included in the outbreak are provided 
in the ‘Results’ section.
Ethical considerations
As this study was conducted as an outbreak 
investigation for IPAC purposes, informed 
consent of patients was not obtained on the 
grounds that specimen collection was based on 
routine clinical practice and infection control 
requirements. The investigation was approved 
by the Human Research Ethics Committee of 
the University of Cape Town (Ref: 534/2012).
Bacterial identification and 
genotypic typing
All stool specimens or rectal swabs were 
plated onto MacConkey agar containing 
4 µg/mL gentamicin. The resulting colonies 
were subsequently identified using the Vitek 
2 system (GN and N133 card, bioMérieux, 
France) and their antibiotic susceptibility 
profiles determined (Vitek 2). All isolates with 
reduced susceptibility to the carbapenems were 
screened for phenotypic carbapenemase activity 
using the modified Hodge test. The minimum 
inhibitory concentrations of carbapenems 
available in this hospital (ertapenem, imipenem 
and meropenem) were determined using the 
E-test method (bioMérieux, France). All tests 
were done and interpreted according to the 
Clinical Laboratory Standards Institute criteria 
(CLSI-2012).[16]
Conventional polymerase chain reaction 
(PCR) assays were performed using, as 
template, either total cellular DNA extracted 
from cultured isolates using the ZR-96 Fungal/
Bacterial DNA kit (Zymo Research, Inqaba, 
South Africa), or total DNA extracted from 
stool and rectal swab specimens using either the 
QiaSymphony (QIAGEN, Germany) or ZR fecal 
DNA Microprep kit (Zymo Research, Inqaba, 
South Africa). All extractions were carried out 
as per the manufacturer’s instructions. PCR 
experiments were performed using PCR 
primers designed to target internal fragments 
of the current most clinically significant 
carbapenemase genes (blaNDM, blaVIM, blaSPM, 
blaIMP, blaKPC, blaGES and blaOXA-48-like) (Table 1). 
The resulting PCR amplicons were purified 
(QIAquick PCR purification kit, QIAGEN, 
Germany) and then sequenced. To test for the 
presence of extended-spectrum β-lactamase 
(ESBL) (Table 1)[17-26] genes blaCTX-M, blaSHV and 
blaTEM, conventional PCR assays using primers 
designed to target internal fragments of these 
genes were performed and any resulting PCR 
amplicons of the expected size were sequenced.
Table 1. Primer sequences used in this study
Primer Sequence (5ʹ - 3ʹ) Gene Reference
Carbapenemases
GESF ATGCGCTTCATTCACGC blaGES 17
GESR GCTCAGGATGAGTTGTG blaGES 17
IMIF ATTGACACTCCATTTAC blaIMI-1 18
IMIR AACAACCAGTTTTGC blaIMI-1 18
NDMF GGTTTGGCGATCTGGTTTTC blaNDM-1 19
NDMR CGGAATGGCTCATCACGATC blaNDM-1 19
OXA48F CGTGTATTAGCCTTATCG blaOXA-48-like 20
OXA48R CGCTAACCACTTCTAGG blaOXA-48-like 20
VIMF GTGAGTATCCGACAGTC blaVIM-1 18
VIMR GAGCAAGTCTAGACCG blaVIM-1 18
KPCF TGTCACTGTATCGCCGTC blaKPC-1 21
KPCR CTCAGTGCTCTACAGAAAACC blaKPC-1 21
SPMF CTGCTTGGATTCATGGGCGC blaSPM-1 22
SPMR CCTTTTCCGCGACCTTGATC blaSPM-1 22
Extended-spectrum β-lactamases
CTXM1F CGCTTTGCGATGTGCAG blaCTX-M-1 17
CTXM1R ACCGCGATATCGTTGGT blaCTX-M-1 17
SHVC AGAAGGGTTATTCTTATTTGTCGC blaSHV 17
SHVD TCTTTCCGATGCCGCCGCCAGTCA blaSHV 23
DEB ATGAGTAAACTTGGTCTGAC blaTEM 24
3061TEM AGGAAGCAAAGCTGAAAGGAATCAAATTTGG blaTEM 25
Insertion sequence
ISEcp1F GCAGGTCTTTTTCTGCTCC ISEcp1 transposase 26
ISEcp1R TTTCCGCAGCACCGTTTGC ISEcp1 transposase 26
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To describe the genomic arrangement of the 
identified blaOXA-181 genes in positive isolates 
in relation to the ISEcp1B gene, which had 
previously been shown to be associated with 
the OXA-181 gene,[7] conventional PCR 
was carried out using primers designed to 
amplify an internal fragment of the insertion 
element, ISEcp1B, and an internal portion of 
the OXA-181 gene (Table 1). The resulting 
PCR amplicons were purified (QIAquick 
PCR purification kit) and then sequenced to 
confirm sequence identity.
The relatedness of the Klebsiella isolates 
was investigated using pulsed-field gel electro-
phoresis (PFGE) according to a previously 
published protocol with minor changes.[27] 
Total genomic DNA was digested, in situ, with 
XbaI (New England Biolabs Inc., UK) and the 
resulting DNA fragments were separated by 
electrophoresis using a 1% w/v, 0.5 × TBE-
agarose gel in a CHEF-DRII GeneNavigator 
apparatus (GE Healthcare, USA) with a ramped 
pulse time of 5 - 60 seconds, over 21 hours, at 
a constant voltage of 200 V, in 0.5 × TBE buffer 
maintained at 14°C. The resulting restriction 
profiles were analysed using GelCompar II 
version 5.1 software (Applied Maths, Belgium). 
A dendrogram indicating the UPGMA clus-
tering between the isolates was created using 
the Dice similarity coefficient. The band 
tolerance and optimisation were set at 1.0% 
and a similarity threshold of ≥80% was used to 
define related clusters.[28]
Multilocus sequence typing (MLST), speci-
fic for Klebsiella, was performed using 
seven housekeeping genes as refer ence 
loci (rpoB, gapA, mdh, pgi, phoE, infB, 
and tonB) according to the method 
described by Diancourt et al.,[29] with 
minor amendments. Allele and sequence 
types were determined using the Insti-
tut Pasteur MLST online database for 
K. pneumoniae.[30]
Results
Outbreak investigation
Review of laboratory records showed that 
no carbapenem-resistant Enterobacteriaceae 
had been detected prior to 12 May 2012. A 
total of 340 rectal swabs or stool specimens, 
from patients and staff members, were 
collected and screened for carriage of 
carbapenem-resistant Enterobacteriaceae. A 
total of eight patients with carbapenem-
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Fig. 1. Timeline and transmission opportunities among the patients during the outbreak. A transmission 
opportunity was deemed to have occurred if two patients were in the same ward during the same time period.
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Fig. 2. Floor plan of the shared haematology ICU in the hospital, showing the location of the patients identified with carbapenem-resistant Klebsiella during 
May 2012. Starred rooms indicate locations of affected case patients. (WC = water closet (toilet); S/SH = shower.)
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resistant Klebsiella were identified from 
12 to 31 May 2012. The eight patients 
were either infected (blood culture, n=1) 
or colonised (pus swab, stool, sputum or 
tracheal aspirate, n=7). No carbapenem-
resistant Enterobacteriaceae were identified 
from the rectal swab specimens submitted by 
the healthcare workers (HCWs). A timeline 
of the outbreak is depicted in Fig. 1.
Patient characteristics
A summary of the patients’ demographic 
and clinical information is provided in 
Table 2. The median age was 48 years (range 
30 - 77 years) and half of the patients were 
male. The median hospitalisation time was 
16 days (range 3 - 29 days). All patients 
had underlying malignancies, were receiving 
cancer chemotherapeutic treatment and 
had been previously exposed to multiple 
antibiotics, placing them at high risk for 
acquiring nosocomial infections.
A timeline for detection of carbapenem-
resistant Klebsiella isolates indicated that 
the outbreak occurred over a 2-week period 
from 12 to 28 May. The floor plan of the 
affected ICU indicates the placement of 7 of 
the 8 patients (Fig. 2). Patients 1, 2, 3, 4, 7 
and 8 were either placed in the same room 
as a previous case or in adjacent rooms in 
close proximity to communal areas, while 
patient  5 was in close proximity to the 
doctors’ room and a common staff room. 
Seven of the eight patients were admitted to 
the shared haematology unit for the duration 
of their hospital stay. The remaining patient 
(patient 6), who had a respiratory tract 
colonisation, was identified in a separate 
ICU, but could be epidemiologically linked 
to patient 1 because he was transferred and 
admitted to the bed adjacent to patient 6. 
Patient 1 died from a bloodstream infection 
(6 hours post transfer), and 8 days later a 
carbapenem-resistant K. pneumoniae was 
cultured from an endotracheal specimen 
from patient 6.
Infection control
During the inspection of the IPAC practices 
in the affected ICU, breaches in contact 
precaution including lack of use of aprons 
and gloves by HCWs before entering patient 
rooms, incorrect disposal of these items 
and poor hand hygiene were observed. 
In addition, incorrect signage relating to 
standard IPAC practices and inadequate 
signage for patients about contact pre-
cautions was also documented.
Microbiological characterisation  
of Klebsiella isolates
A total of eight carbapenem-resistant Kleb-
siella isolates (seven K. pneumoniae and one 
K. oxytoca) were identified. All eight isolates 
exhibited a multidrug-resis tance phenotype 
with resistance to ampi cillin, co-amoxiclav, 
cefuroxime, cefoxitin, cefotaxime, cefta-
zidime, cefe pime, genta micin, amikacin, 
tigecycline, co-trimoxazole, nalidixic acid 
and ciprofloxacin, and were susceptible 
to colistin only. Carbapenem minimum 
inhibitory concentration (MIC) patterns are 
shown in Table 2. The isolates demonstrated 
variable susceptibility to imipenem with 
reduced susceptibility to both meropenem 
(range 8 - >32 mg/L) and ertapenem (all 
>32  mg/L). The modified Hodge test was 
positive for all eight isolates. [31]
Conventional PCR for OXA-48 and OXA-
48-like genes generated amplicons of the 
expected size for all eight isolates. Subsequent 
sequence analysis revealed that all eight 
PCR positive isolates had 100% homology 
with blaOXA-181, a genetic variant of blaOXA-48. 
Similar results were obtained from DNA 
extracted from the corresponding rectal 
swabs or stool samples. No amplicons were 
obtained for the other carbapenemase genes 
screened: blaNDM, blaVIM, blaIMP, blaKPC, blaSPM 
and blaGES. All eight isolates were positive 
on ESBL PCR screening for blaCTX-M, blaTEM 
and blaSHV (with the exception of K. oxytoca, 
which did not contain blaSHV), as shown in 
Table 2.
Genetic arrangement of the blaOXA-181
Using the forward primer targeting 
ISEcp1B and the reverse primer internal to 
blaOXA-181, an amplicon of the expected size 
was obtained, suggesting these genes are 
associated in all eight isolates.
Phylogenetic analysis
To establish the relatedness of the seven 
K. pneumoniae isolates, PFGE analysis was 
carried out. K. pneumoniae isolate 4 was not 
viable. The resultant PFGE fingerprints of 
six of the K. pneumoniae isolates, patients 
1, 2, 3, 5, 6, and 8, were indistinguishable 
(100% identity) and were assigned to 
cluster A (Fig. 3). Two contemporary 
K.  pneumoniae isolates, one from another 
ward (carbapenem susceptible) and one 
from another local hospital (carbapenem 
Table 2. Demographic information, PCR and microbiological results of patients identified with carbapenem-resistant Klebsiella spp.
Patient 
identity Isolate identity
Date of 
isolation Gender
Age 
(y)
Specimen 
type
Clinical 
outcome
MIC (mg/L)
MHT
Carbapenemase 
genes ESBL genesEP IP MP
Case 1 K. pneumoniae 12/05/2012 M 77 Blood Deceased >32 6 16  + blaOXA-181 blaCTX-M-15, blaTEM, 
blaSHV
Case 2 K. pneumoniae 12/05/2012 M 36 Stool Survived >32 4 >32  + blaOXA-181 blaCTX-M-15, blaTEM, 
blaSHV
Case 3 K. pneumoniae 17/05/2012 M 44 Stool Survived >32 1.5 8  + blaOXA-181 blaCTX-M-15, blaTEM, 
blaSHV
Case 4 K. pneumoniae 18/05/2012 F 52 Stool Deceased* N/D 4 N/D  + blaOXA-181 blaCTX-M-15, blaTEM, 
blaSHV
Case 5 K. pneumoniae 19/05/2012 F 57 Stool Survived >32 8 >32  + blaOXA-181 blaCTX-M-15, blaTEM, 
blaSHV
Case 6 K. pneumoniae 21/05/2012 F 51 Tracheal 
aspirate
Survived >32 4 >32  + blaOXA-181 blaCTX-M-15, blaTEM, 
blaSHV
Case 7 K. oxytoca 21/05/2012 F 41 Stool Survived >32 >32 16  + blaOXA-181 blaCTX-M-15, blaTEM
Case 8 K. pneumoniae 24/05/2012 M 30 Stool & 
pus swab
Survived >32 4 16  + blaOXA-181 blaCTX-M-15, blaTEM, 
blaSHV
EP = ertapenem; IP = imipenem; MP = meropenem; MHT = modified Hodge test.
*Died from causes unrelated to K. pneumoniae infection. 
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resistant) were included in the analysis and 
shown to be unrelated to cluster A. The 
K. oxytoca isolate from patient 7 was, as 
expected, genetically distinct from all the 
K. pneumoniae strains tested. Since the six 
K. pneumoniae isolates had the same PFGE 
profile, MLST analysis was only carried 
out on two representative K.  pneumoniae 
isolates, case numbers 6 and 4. The results 
were analysed using the Pasteur database 
and showed that these two strains are both 
members of sequence type ST14.
Discussion and 
conclusions
This study describes the first documented 
nosocomial outbreak of blaOXA-181-producing, 
carbapenem-resistant K. pneumoniae and 
K. oxytoca isolated from a local tertiary aca-
demic hospital in Cape Town. Resistance 
to the clinically significant carbapenem 
antibiotics by enzymatic hydrolysis has been 
described in Enterobacteriaceae worldwide, 
and recently the class D β-lactamase, OXA-
48 and its variants have been detected more 
frequently.[4] While the blaOXA-181 gene has 
previously been identified in several clonally 
unrelated K. pneumoniae isolates from 
SA, India, Singapore, the Netherlands and 
New Zealand,[4-12] this is the first report 
describing an outbreak of blaOXA-181 in SA. To 
our knowledge this is the first identification 
of a blaOXA-181-producing K.  oxytoca isolate. 
Although it remains unclear where 
this organism originated, and since no 
international travel link could be established 
for any of the patients, there is evidence 
to suggest that OXA-181 may have been 
prevalent in a nearby private sector hospital 
that could have been a possible source of this 
organism in the community.[6] The profiles 
of six of the K. pneumoniae isolates, patients 
1, 2, 3, 5, 6, and 8, were indistinguishable and 
were assigned to cluster A. Two contempor-
ary K. pneumoniae isolates, one from another 
ward (carbapenem-susceptible) and one 
from another local hospital (carbapenem-
resistant), were included in the analysis and 
shown to be unrelated to cluster A. PFGE 
is no longer considered the gold standard 
for genetic typing because of its lack of 
discrimination. Therefore, to characterise 
the genetic background of this clone further, 
MLST of two representative isolates from 
cluster A, spanning the defined outbreak 
period, were selected. MLST indicated that 
these two isolates belonged to sequence 
type ST14. K. pneumoniae ST14 has on 
two previous occasions been associated with 
ESBLs and not with metallo-β-lactamases or 
serine carbapenemases, as was observed in 
these isolates.[10,11]
All OXA-181-containing isolates in this 
study were resistant to carbapenems and 
positive for carbapenemase production by 
the modified Hodge test. The co-production 
of OXA-181 with ESBL enzymes and the 
accumulation of additional β-lactamase 
genes in Enterobacteriaceae has been shown 
to collectively produce an elevated multidrug-
resistance phenotype.[4,7,9,10] A probable 
explanation for the uncharacteristically 
high carbapenem resistance levels observed 
with these isolates was the presence of 
additional ESBL genes. Furthermore, the 
OXA-181 gene was shown to be linked to 
the ISEcp1B element, which has been shown 
to up-regulate gene expression and allow for 
gene mobilisation.[7] Further investigations 
are underway to determine the plasmid 
types of these isolates to better elucidate 
reasons for its successful spread.
The IPAC report documented inadequate 
infection control practices among healthcare 
staff in the shared haematology unit, and it 
is possible that this breakdown in infection 
control practices contributed to the spread 
of this organism between patients, either 
directly via the hands of staff or via fomites. 
It was observed among HCWs that breaches 
in contact precautions, including the lack of 
aprons and gloves prior to entering patient 
rooms, as well as the incorrect disposal of 
these items, and overall poor hand hygiene 
could have contributed to the spread of 
this organism. HCWs were encouraged to 
submit faecal samples for the screening 
of gut carriage of carbapenem-resistant 
Enterobacteriaceae as a possible source of 
the outbreak. This investigation could not 
rule out transmission in other communal 
areas, such as the radiology department 
or procedure rooms used for implanting 
medical devices. Further case-control 
analysis of patient and provider risk factors 
would have strengthened this investigation. 
In addition, this study could not clearly 
identify an index patient, given the 
inconsistent compliance with surveillance 
screening policy prior to the outbreak. 
The following recommendations were 
made based on the IPAC report from this 
investigation: stricter adherence to laboratory 
screening for antibiotic-resistant organisms 
from routine surveillance rectal swabs 
of new patients, both on admission and 
weekly follow-up, as well as the re-education 
and adherence to IPAC among all staff 
(temporary and full time). Additionally, 
improved IPAC signage practices that will 
increase awareness among hospital staff, the 
identification of IPAC awareness champions 
and developing a multidisciplinary team 
to maintain awareness should be consi-
dered. Ultimately, timely identification 
of the organism, swift unit closure and a 
reduction in patient movement coupled 
with strict contact precautions for colonised 
patients were effective in limiting further 
transmission of this isolate, as there were no 
new cases identified after 28 May. However, 
given the ongoing circulation of patients 
between local hospitals, and the potential for 
long-term asymptomatic carriage, it is likely 
that carbapenem-resistant Klebsiella will 
be reintroduced in the future. Vulnerable 
patients with haematological malignancies 
are likely to manifest infections as a result 
of multidrug-resistant organisms, including 
carbapenem-resistant Klebsiella.
In summary, this outbreak demonstrates 
the importance of active surveillance 
coupled with rapid and accurate molecular 
geno typic testing in enabling the detection 
and subsequent control of carbapenemase-
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Fig. 3. Dendrogram and PFGE DNA fingerprints generated by XbaI restriction enzyme treatment of 
OXA-181-producing K. pneumoniae isolates (patient cases 1, 5, 6, 2, 8, 3) and one K. oxytoca (patient 
case 7). Two contemporary K. pneumoniae isolates, one from another ward (carbapenem-susceptible, 
contemporary isolate) and one from another local hospital (carbapenem-resistant, contemporary isolate 
2) were included in the analysis as outliers.
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producing Klebsiella. This work highlights the necessity of not only 
ensuring that effective infection control measures are in place to 
identify and limit the spread of such organisms, but also the added 
value molecular screening offers in confirming an outbreak by 
determining the molecular epidemiology of the bacterial isolates and 
the prevalence of resistance genes circulating in our hospitals and 
communities.
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